Sharon Dealing
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Rehabilitation top 5%
- Stroke Rehabilitation and Recovery
Papers in
-
- COVID-19 Clinical Research Studies 9
-
- Antiplatelet Therapy and Cardiovascular Diseases 1
- Atrial Fibrillation Management and Outcomes 1
Sharon Dealing
13 papers receiving 1.9k citations
Sharon Dealing's Hit Papers
Peers
Comparison fields: 5 of 95
- Infectious Diseases 1.3k
- Rehabilitation 133
- Applied Microbiology and Biotechnology 35
- Internal Medicine 29
- Epidemiology 166
Countries citing papers authored by Sharon Dealing
This map shows the geographic impact of Sharon Dealing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Dealing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Dealing more than expected).
Fields of papers citing papers by Sharon Dealing
This network shows the impact of papers produced by Sharon Dealing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Dealing. The network helps show where Sharon Dealing may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2018 | 217 | |
| 6 | 2021 | 213 | |
| 7 | 2017 | 130 | |
| 8 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 9 | 2023 | 25 | |
| 10 | 2019 | 24 | |
| 11 | 2024 | 24 | |
| 12 | 2025 | 5 | |
| 13 | 2025 | 2 | |
| 14 | 2025 | 0 |
About Sharon Dealing
Sharon Dealing is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine, Rehabilitation, Epidemiology and Surgery, having authored 14 papers that have together received 2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (9 papers), Acute Ischemic Stroke Management (2 papers), Antiplatelet Therapy and Cardiovascular Diseases (1 paper), Kawasaki Disease and Coronary Complications (1 paper), Atrial Fibrillation Management and Outcomes (1 paper) and Stroke Rehabilitation and Recovery (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Rehabilitation (133 citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (29 citations) and Epidemiology (166 citations). Sharon Dealing has collaborated with scholars based in United Kingdom, New Zealand and Nepal. Their work appears in journals such as The Lancet, EClinicalMedicine, Journal of the American Heart Association, The Lancet Infectious Diseases and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.